<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E594C221-4738-4152-9CFD-57F6EB31C620"><gtr:id>E594C221-4738-4152-9CFD-57F6EB31C620</gtr:id><gtr:name>Fraunhofer Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/119C5534-C0BC-4310-8481-C7E06B395A08"><gtr:id>119C5534-C0BC-4310-8481-C7E06B395A08</gtr:id><gtr:name>General Electric (GE)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DCDFE09D-1A1A-4FAE-8C08-8CFF70891B3A"><gtr:id>DCDFE09D-1A1A-4FAE-8C08-8CFF70891B3A</gtr:id><gtr:name>Meso Scale Delivery</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/58704C20-A72D-49C0-BE60-977383C307F5"><gtr:id>58704C20-A72D-49C0-BE60-977383C307F5</gtr:id><gtr:name>Araclon Biotech</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0407B94D-DABF-4B46-B5F0-2CBDC1C63C67"><gtr:id>0407B94D-DABF-4B46-B5F0-2CBDC1C63C67</gtr:id><gtr:name>national Institute on Aging</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D7900CE2-A312-427D-AB82-2F88341AE2B5"><gtr:id>D7900CE2-A312-427D-AB82-2F88341AE2B5</gtr:id><gtr:name>SomaLogic</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E594C221-4738-4152-9CFD-57F6EB31C620"><gtr:id>E594C221-4738-4152-9CFD-57F6EB31C620</gtr:id><gtr:name>Fraunhofer Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/119C5534-C0BC-4310-8481-C7E06B395A08"><gtr:id>119C5534-C0BC-4310-8481-C7E06B395A08</gtr:id><gtr:name>General Electric (GE)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DCDFE09D-1A1A-4FAE-8C08-8CFF70891B3A"><gtr:id>DCDFE09D-1A1A-4FAE-8C08-8CFF70891B3A</gtr:id><gtr:name>Meso Scale Delivery</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/58704C20-A72D-49C0-BE60-977383C307F5"><gtr:id>58704C20-A72D-49C0-BE60-977383C307F5</gtr:id><gtr:name>Araclon Biotech</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0407B94D-DABF-4B46-B5F0-2CBDC1C63C67"><gtr:id>0407B94D-DABF-4B46-B5F0-2CBDC1C63C67</gtr:id><gtr:name>national Institute on Aging</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D7900CE2-A312-427D-AB82-2F88341AE2B5"><gtr:id>D7900CE2-A312-427D-AB82-2F88341AE2B5</gtr:id><gtr:name>SomaLogic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9F8CC320-37A6-4F70-BCF6-661FD4E76478"><gtr:id>9F8CC320-37A6-4F70-BCF6-661FD4E76478</gtr:id><gtr:firstName>Malcolm</gtr:firstName><gtr:surname>Ward</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9B8C6561-A7B1-4005-94C5-F62552C54593"><gtr:id>9B8C6561-A7B1-4005-94C5-F62552C54593</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Lovestone</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/09717709-C72F-4D1D-A890-7310F654D410"><gtr:id>09717709-C72F-4D1D-A890-7310F654D410</gtr:id><gtr:firstName>Carol</gtr:firstName><gtr:surname>Brayne</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801464"><gtr:id>C06252F3-EACA-44BE-A554-6E8E5275258D</gtr:id><gtr:title>Evaluation of a plasma protein panel as a compound biomarker for Alzheimers disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801464</gtr:grantReference><gtr:abstractText>Alzheimer?s disease is one of the most common and devastating of diseases of the elderly. As the population ages then the costs, already larger than cancer and heart disease combined, are set to rise substantially. Progress is being made in understanding the disease pathogenesis with the first disease modifying trials being reported this year. However, despite this progress, Alzheimer?s remains difficult to diagnose in the early stages, impossible to predict and even monitoring disease progression is difficult and subject to day to day variation and other sources of error. One way of overcoming these problems is the use of tests or biomarkers. Many such tests in development are dependent on access to sophisticated brain scanning or spinal fluid. We have taken an alternative approach in seeking blood based biomarkers. Studies in our laboratories over the past five years have revealed a set of markers that differ between Alzheimer?s patients and other elderly people. We propose now to develop these further into a test and then to trial this test on a large number of people. We will determine in this way, whether these proteins, together or separately, do function as a test in Alzheimer?s disease either for early diagnosis, for prediction of dementia or for monitoring disease progression. If they do, and the evidence so far is promising, then this has the potential to substantially improve diagnosis and to make trials of drugs for Alzheimer?s faster and more accurate to perform.</gtr:abstractText><gtr:technicalSummary>Using gel based proteomics we have identified a panel of potential plasma biomarkers for Alzheimer?s disease. These proteins have been replicated in moderately large subject populations of 200-500 subjects and subsequently the same proteins or closely related proteins have been identified in similar, independent studies, including those of our collaborators. These proteins together show promise as a compound marker for Alzheimer?s disease ? for example a sub-set of just five of the proteins predict brain volume, a marker of disease, in 80% of subjects. Having replicated, or partially validated, this set of proteins we now need to develop a stable and fully quantitative and sensitive assay and to test this on very large numbers of subjects, including population based cohorts. We plan to develop dual immunocapture and mass spectrometry based multiplexed assays and in a staged design determine the characteristics of the resulting compound assay as a marker of diagnosis, prediction and progression. We have, through this collaborative group, assembled a very large set of well characterised subjects for such studies including the main US and European AD Biomarker collections and population based sample sets including the MRC CFAS study. The study led by the MRC Centre for Neurodegeneration brings together expertise in Alzheimer?s disease, in assay design and development, in population based analyses and in statistics. The set of markers we have developed to date are, to our knowledge, the best characterised set developed through proteomics and are ready for further development and translation to clinical utility.</gtr:technicalSummary><gtr:fund><gtr:end>2012-02-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-02-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>696092</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute on Aging</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NIA joint biomarker initiative</gtr:description><gtr:id>003D1D86-6964-43C1-9824-CC962104512A</gtr:id><gtr:impact>Ongoing collaborations with multiple publications</gtr:impact><gtr:outcomeId>HCRibDHUH6V-1</gtr:outcomeId><gtr:partnerContribution>Samples, PI time, intellectual engagement, finding</gtr:partnerContribution><gtr:piContribution>We have forged a funded collaboration with the NIA (via Madhave Thambisetty) to collaborate on dementia biomarkers using the US sample collections. We provide all wet-lab and together work on informatics analysis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Araclon Biotech</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>DPUK Biomarkers</gtr:description><gtr:id>576B3934-2F34-4DDE-BDB9-F8F6136D0840</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dae70bb61384.76539306-3</gtr:outcomeId><gtr:partnerContribution>Based on the biomarker work we have developed, the companies MSD, Araclon and SomaLogic have joined as partners to Dementias Platform UK. The specific biomarkers we have developed and published will be implemented now on the MSD platform and using this and SomaLogic platform tested for validation in the DPUK</gtr:partnerContribution><gtr:piContribution>Based on the biomarker work we have developed, the companies MSD, Araclon and SomaLogic have joined as partners to Dementias Platform UK. The specific biomarkers we have developed and published will be implemented now on the MSD platform and using this and SomaLogic platform tested for validation in the DPUK</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fraunhofer Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Fraunhofer Institute for Algorithms and Scientific Computing</gtr:department><gtr:description>Collaboration with Fraunhofer and AETIONOMY</gtr:description><gtr:id>326C411A-6DB0-4F7A-8CF5-4BDD576183AE</gtr:id><gtr:impact>Too soon for outcomes</gtr:impact><gtr:outcomeId>58c3066aaf9cb5.85180307-1</gtr:outcomeId><gtr:partnerContribution>The Franunhofer / AETIONOMY group have generated a systems approach to determining pathways and mechanisms in neurodegeneration and we will work together utilising their Big Data analytics and tools and our Neural Networks/NLP approach and data to validate and extend their models.</gtr:partnerContribution><gtr:piContribution>We have established a collaboration with Martin Hoffmann-Apitius at Fraunhofer SCAI with funding from UCB via the AETIONOMY programme. The funding is an estimate at present and is for a post-doctoral research worker for two years. The collaboration is to utilise the datasets we have generated together with our access to and knowledge of EHRs. We will also contribute informatics expertise and deep learning/neural networks to the collaboration</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Calum Sutherland</gtr:description><gtr:id>521BC2EB-1B24-46C5-8BF6-8F59AAED2919</gtr:id><gtr:impact>Clinical and biochemical expertise</gtr:impact><gtr:outcomeId>56dae58372f5a5.51132636-1</gtr:outcomeId><gtr:partnerContribution>New grant: PRELIMINARY EVALUATION OF THE THERAPEUTIC POTENTIAL OF LITHIUM IN MILD COGNITIVE IMPAIRMENT
Funded by CSO Scotland

Shared study to explore further therapeutic potential of lithium and target engagement biomarkers for AD</gtr:partnerContribution><gtr:piContribution>New grant: PRELIMINARY EVALUATION OF THE THERAPEUTIC POTENTIAL OF LITHIUM IN MILD COGNITIVE IMPAIRMENT
Funded by CSO Scotland

Shared study to explore further therapeutic potential of lithium and target engagement biomarkers for AD</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Meso Scale Delivery</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>DPUK Biomarkers</gtr:description><gtr:id>E0213899-843F-4259-800D-08E40CF01A2D</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dae70bb61384.76539306-1</gtr:outcomeId><gtr:partnerContribution>Based on the biomarker work we have developed, the companies MSD, Araclon and SomaLogic have joined as partners to Dementias Platform UK. The specific biomarkers we have developed and published will be implemented now on the MSD platform and using this and SomaLogic platform tested for validation in the DPUK</gtr:partnerContribution><gtr:piContribution>Based on the biomarker work we have developed, the companies MSD, Araclon and SomaLogic have joined as partners to Dementias Platform UK. The specific biomarkers we have developed and published will be implemented now on the MSD platform and using this and SomaLogic platform tested for validation in the DPUK</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Neuroscience Johnson and Johnson</gtr:department><gtr:description>Joint collaborative studies (CONFIDENTIAL)</gtr:description><gtr:id>41B54546-26AA-4D09-92E4-9C450C8FE499</gtr:id><gtr:impact>Multidisciplinary teams from all three partners including imaging, informatics and proteomics expertise.</gtr:impact><gtr:outcomeId>dGeWYiAcgeY-1</gtr:outcomeId><gtr:partnerContribution>J&amp;amp;J providing data and considerable informatics time and expertise. GEHC providing samples and imaging analysis time and expertise. Funding provided by the companies to KCL in excess of &amp;pound;200k</gtr:partnerContribution><gtr:piContribution>A joint initiative between J&amp;amp;J, GEHC and KCL. We are generating new data on samples provided and together with the companies are jointly analysing our datasets as biomarkers for Alzheimer's disease. This is a substantial collaboration with bi-weekly telephone conferences and 6-monthly face to face meetings</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SomaLogic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>DPUK Biomarkers</gtr:description><gtr:id>333927D3-9780-488D-897B-9B4413101EC9</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dae70bb61384.76539306-2</gtr:outcomeId><gtr:partnerContribution>Based on the biomarker work we have developed, the companies MSD, Araclon and SomaLogic have joined as partners to Dementias Platform UK. The specific biomarkers we have developed and published will be implemented now on the MSD platform and using this and SomaLogic platform tested for validation in the DPUK</gtr:partnerContribution><gtr:piContribution>Based on the biomarker work we have developed, the companies MSD, Araclon and SomaLogic have joined as partners to Dementias Platform UK. The specific biomarkers we have developed and published will be implemented now on the MSD platform and using this and SomaLogic platform tested for validation in the DPUK</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>General Electric (GE)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Joint collaborative studies (CONFIDENTIAL)</gtr:description><gtr:id>58F39EF6-C1E8-467C-8C2E-6A74423209E1</gtr:id><gtr:impact>Multidisciplinary teams from all three partners including imaging, informatics and proteomics expertise.</gtr:impact><gtr:outcomeId>dGeWYiAcgeY-2</gtr:outcomeId><gtr:partnerContribution>J&amp;amp;J providing data and considerable informatics time and expertise. GEHC providing samples and imaging analysis time and expertise. Funding provided by the companies to KCL in excess of &amp;pound;200k</gtr:partnerContribution><gtr:piContribution>A joint initiative between J&amp;amp;J, GEHC and KCL. We are generating new data on samples provided and together with the companies are jointly analysing our datasets as biomarkers for Alzheimer's disease. This is a substantial collaboration with bi-weekly telephone conferences and 6-monthly face to face meetings</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>schools and lay groups</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4444E547-84FF-45A9-AF27-C5D7B7D5460C</gtr:id><gtr:impact>This work has been incorporated into multiple public dissemination outputs

No subsequent impact</gtr:impact><gtr:outcomeId>07179ECB0DB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>7000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>John and Lucille van Geest Foundation</gtr:department><gtr:description>Not applicable (possibly confidential)</gtr:description><gtr:fundingOrg>University of Leicester</gtr:fundingOrg><gtr:fundingRef>CONFIDENTIAL INFORMATION</gtr:fundingRef><gtr:id>BA19975F-C729-46CC-A1E0-F6C66F9AD4A6</gtr:id><gtr:outcomeId>jW7FpP7yxfZ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Strategic Awards - Neuroinflammation consortium</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>EA55B619-AA17-4055-9A84-8E1CD7545B16</gtr:id><gtr:outcomeId>5458b326a37362.63042660</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>48000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>IMI EMIF</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>00A7B956-2EB1-47FF-AF02-926C48A3BE26</gtr:id><gtr:outcomeId>TSoyq6h2skn</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Alzheimer's society studentships</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Alzheimer?s Society</gtr:fundingOrg><gtr:id>F824AD60-2CB1-4373-B853-07A5D6737326</gtr:id><gtr:outcomeId>pYW3h2mQFcH</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>See http://www.proteomics.com/products-and-services/cns/alzheimer-s-plasma-9-plex

Developed jointly with KCL directly as a consequence of MRC funding</gtr:description><gtr:id>3F0CDDFE-B594-4FAF-B4FA-6DA233B1F53B</gtr:id><gtr:impact>Considerable impact in the course of development including further funding</gtr:impact><gtr:outcomeId>PhLziLwGghE</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Alzheimer's Plasma 9-plex Assay</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://www.proteomics.com/products-and-services/cns/alzheimer-s-plasma-9-plex</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2C40AC47-51FD-432D-83B0-8F3965E5E15B</gtr:id><gtr:title>Mitochondrial genes are altered in blood early in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/878e2d05b1e177f10ea100a84346398f"><gtr:id>878e2d05b1e177f10ea100a84346398f</gtr:id><gtr:otherNames>Lunnon K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5a949c576b6a11.48035066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F732BC8B-514D-4376-BE0D-2535B52E268D</gtr:id><gtr:title>Predicting progression of Alzheimer's disease using ordinal regression.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c66500625ad889fb130796efe084218f"><gtr:id>c66500625ad889fb130796efe084218f</gtr:id><gtr:otherNames>Doyle OM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5458ace56cdc62.66126331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE1ED46E-7771-4DC8-A47A-19C725201A19</gtr:id><gtr:title>Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c63274d0f68e432664a85925aa57f816"><gtr:id>c63274d0f68e432664a85925aa57f816</gtr:id><gtr:otherNames>O'Bryant SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>5458ace621a208.42221478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CAD0692-EBA6-4FCA-B29E-1086F899E75E</gtr:id><gtr:title>Effects of freezer storage time on levels of complement biomarkers.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5109e1a98eef0b7d0fee05867d6f9d86"><gtr:id>5109e1a98eef0b7d0fee05867d6f9d86</gtr:id><gtr:otherNames>Morgan AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>5a949c56d1a163.05244428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D88F018C-53A5-455C-9A72-F964332EB1CE</gtr:id><gtr:title>The future of blood-based biomarkers for Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1414f5e5a3bdb4620d9836489b816364"><gtr:id>1414f5e5a3bdb4620d9836489b816364</gtr:id><gtr:otherNames>Henriksen K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>pm_14948_28_23850333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF17B9CF-6E1E-4BA6-89A5-ECC9AEDA2ED4</gtr:id><gtr:title>Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a722b01d637c7274ec6a5c463f37987"><gtr:id>9a722b01d637c7274ec6a5c463f37987</gtr:id><gtr:otherNames>Sattlecker M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>pm_14948_28_24768341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1A4200A-9C8D-4028-8727-242424013B86</gtr:id><gtr:title>Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29c93f2d9d4c754ff4c4362079eb33d8"><gtr:id>29c93f2d9d4c754ff4c4362079eb33d8</gtr:id><gtr:otherNames>Hakobyan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>5834344adb52b7.26717949</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0A5B60F-CE33-44F2-AB5B-F780426A13E7</gtr:id><gtr:title>Developing novel blood-based biomarkers for Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73e96b7d526b66cd7d3a2bed57b9b4eb"><gtr:id>73e96b7d526b66cd7d3a2bed57b9b4eb</gtr:id><gtr:otherNames>Snyder HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>pm_14948_28_24365657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EE02A37-0169-4433-AFF4-59906D3D327C</gtr:id><gtr:title>Plasma transthyretin as a candidate marker for Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5623026c7b4b72187698f4688c48b355"><gtr:id>5623026c7b4b72187698f4688c48b355</gtr:id><gtr:otherNames>Velayudhan L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>pm_14948_28_22002789</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A4397FD-DEAF-4C52-95FB-945E98587E23</gtr:id><gtr:title>Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/995d17b793718fee7013ae3329efac4f"><gtr:id>995d17b793718fee7013ae3329efac4f</gtr:id><gtr:otherNames>Westwood S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>5834344892bd58.91191655</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFC9EC6F-4CD4-4890-A558-3DA63311462F</gtr:id><gtr:title>Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology.</gtr:title><gtr:parentPublicationTitle>Frontiers in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7553f1acef97f326e1e384a45a3748b0"><gtr:id>7553f1acef97f326e1e384a45a3748b0</gtr:id><gtr:otherNames>Baird AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-2295</gtr:issn><gtr:outcomeId>58343447163559.02070640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE330D81-FFFE-421B-A43E-2E4C206742E5</gtr:id><gtr:title>The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology.</gtr:title><gtr:parentPublicationTitle>Alzheimer's research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/995d17b793718fee7013ae3329efac4f"><gtr:id>995d17b793718fee7013ae3329efac4f</gtr:id><gtr:otherNames>Westwood S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a949c57018149.16362401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6216E981-F8E3-4FC9-8259-804933620439</gtr:id><gtr:title>Blood protein predictors of brain amyloid for enrichment in clinical trials?</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia (Amsterdam, Netherlands)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b44e6b573b2b98ca3198c8bb23c5ff22"><gtr:id>b44e6b573b2b98ca3198c8bb23c5ff22</gtr:id><gtr:otherNames>Ashton NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>58343446d84830.38192202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7B8B29F-985A-4BDC-B8D1-E2736E8D4C06</gtr:id><gtr:title>A blood gene expression marker of early Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/878e2d05b1e177f10ea100a84346398f"><gtr:id>878e2d05b1e177f10ea100a84346398f</gtr:id><gtr:otherNames>Lunnon K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>pm_14948_28_23042217</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE68E4DB-F53E-41FC-B2AE-ECD451C2BD56</gtr:id><gtr:title>Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a722b01d637c7274ec6a5c463f37987"><gtr:id>9a722b01d637c7274ec6a5c463f37987</gtr:id><gtr:otherNames>Sattlecker M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>56595ada64a5d2.34545760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9FDE144-1146-4726-B73A-4F417A00C68A</gtr:id><gtr:title>Circulating Proteomic Signatures of Chronological Age.</gtr:title><gtr:parentPublicationTitle>The journals of gerontology. Series A, Biological sciences and medical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b59a04012f7a6ac0423f796b24b0bc13"><gtr:id>b59a04012f7a6ac0423f796b24b0bc13</gtr:id><gtr:otherNames>Menni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1079-5006</gtr:issn><gtr:outcomeId>5458ace51d5d83.67399940</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE47F7E8-F746-47C5-96E9-0346DD3151AC</gtr:id><gtr:title>Plasma proteins predict conversion to dementia from prodromal disease.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b948558278fbd5ba69e9d363283165b"><gtr:id>6b948558278fbd5ba69e9d363283165b</gtr:id><gtr:otherNames>Hye A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>5458ace4bcd610.79536490</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801464</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>